Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/12263
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Choline kinase alpha depletion selectively kills tumoral cells |
Autor: | Báñez Coronel, Mónica CSIC; Ramírez de Molina, Ana CSIC ORCID; Rodríguez-González, Agustín; Sarmentero, Jacinto; Ramos, Mª Angeles; García Cabezas, Miguel Ángel; Garcia-Oroz, Lourdes; Lacal, Juan Carlos CSIC ORCID | Palabras clave: | Choline Kinase Anticancer drugs Target validation Apoptosis ChoK Inhibitors ShRNA |
Fecha de publicación: | dic-2008 | Editor: | Bentham Science Publishers | Citación: | Current Cancer Drug Targets. 2008 Dec;8(8):709-19 | Resumen: | Choline Kinase (ChoK) comprises a family of cytosolic enzymes involved in the synthesis of phosphatidylcholine (PC), the most abundant phospholipid in eukaryotic cell membranes. One of the ChoK isoforms, Choline Kinase α (ChoKα), is found over expressed in human tumours. Chemical inhibitors able to interfere with ChoK activity have proven to be effective antitumoral drugs in vitro and in vivo. To validate the use of selective ChoKα inhibitors in cancer therapy, we have developed a genetic strategy to interfere specifically with ChoKα activity based on the generation of a shRNA against the alpha isoform of ChoK. Here we demonstrate that specific inhibition of ChoKα by shRNA has antitumor activity. The specific depletion of ChoKα induces apoptosis in several tumor-derived cell lines from breast, bladder, lung and cervix carcinoma tumors, while the viability of normal primary cells is not affected. Furthermore, this selective antiproliferative effect is achieved both under in vitro and in vivo conditions, as demonstrated by an inducible ChoKα suppression system in human tumour xenografts. These results demonstrate that ChoKα inhibition is a useful antitumoral strategy per se, and provides definitive and non-ambiguous evidence that ChoKα can be used as an efficient and selective drug target for cancer therapy | Versión del editor: | http://www.benthamdirect.org/pages/content.php?CCDT/2008/00000008/00000008/0007U | URI: | http://hdl.handle.net/10261/12263 | ISSN: | 1568-0096 |
Aparece en las colecciones: | (CNB) Artículos |
Mostrar el registro completo
CORE Recommender
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.